IL112242A - Monohydrate of (E)-2'-deoxy-2'-(fluoromethylene)cytidine - Google Patents

Monohydrate of (E)-2'-deoxy-2'-(fluoromethylene)cytidine

Info

Publication number
IL112242A
IL112242A IL11224295A IL11224295A IL112242A IL 112242 A IL112242 A IL 112242A IL 11224295 A IL11224295 A IL 11224295A IL 11224295 A IL11224295 A IL 11224295A IL 112242 A IL112242 A IL 112242A
Authority
IL
Israel
Prior art keywords
fluoromethylene
cytidine
deoxy
monohydrate
neoplastic
Prior art date
Application number
IL11224295A
Other languages
English (en)
Other versions
IL112242A0 (en
Original Assignee
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc
Publication of IL112242A0 publication Critical patent/IL112242A0/xx
Publication of IL112242A publication Critical patent/IL112242A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL11224295A 1994-01-07 1995-01-04 Monohydrate of (E)-2'-deoxy-2'-(fluoromethylene)cytidine IL112242A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17895294A 1994-01-07 1994-01-07

Publications (2)

Publication Number Publication Date
IL112242A0 IL112242A0 (en) 1995-03-30
IL112242A true IL112242A (en) 2000-08-31

Family

ID=22654587

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11224295A IL112242A (en) 1994-01-07 1995-01-04 Monohydrate of (E)-2'-deoxy-2'-(fluoromethylene)cytidine

Country Status (20)

Country Link
EP (1) EP0738273B1 (de)
JP (1) JPH09511227A (de)
KR (1) KR100330328B1 (de)
CN (1) CN1043231C (de)
AT (1) ATE186732T1 (de)
AU (1) AU684604B2 (de)
CA (1) CA2179987C (de)
DE (1) DE69421721T2 (de)
DK (1) DK0738273T3 (de)
ES (1) ES2141330T3 (de)
FI (1) FI114396B (de)
GR (1) GR3032614T3 (de)
HU (1) HU217849B (de)
IL (1) IL112242A (de)
MX (1) MX9500363A (de)
NO (1) NO306409B1 (de)
NZ (1) NZ279030A (de)
TW (1) TW397838B (de)
WO (1) WO1995018815A1 (de)
ZA (1) ZA9512B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1130363C (zh) 1997-11-12 2003-12-10 三菱化学株式会社 嘌呤衍生物以及含有其作为有效成分的药物
WO2000068231A1 (en) 1999-05-11 2000-11-16 Mitsubishi Chemical Corporation Purine derivative dihydrate, drugs containing the same as the active ingredient and intermediate in the production thereof
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ras抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA898567B (en) * 1988-11-15 1990-08-29 Merrell Dow Pharma Novel 2'-halomethylidene,2'-ethenylidene and 2'-ethynyl cytidine,uridine and guanosine derivatives
FI95269C (fi) * 1989-05-15 1996-01-10 Squibb Bristol Myers Co 2',3'-dideoksi-inosiinimonohydraatin, 2',3'-dideoksi-2',3'-didehydrot ymidiinimonohydraatin ja 2',3'-dideoksi-2'-fluori-inosiinihemihydraatin antiviraalisia, hyvin vesiliukoisia, stabiileja, kiteisiä suoloja
JPH0615557B2 (ja) * 1990-02-19 1994-03-02 ヤマサ醤油株式会社 2’―デオキシ―2’―メチリデンシチジンの2水和物結晶
JP3265548B2 (ja) * 1992-05-12 2002-03-11 メレルファーマス−ティカルズ インコーポレイテッド リボヌクレオチド還元酵素阻害剤の製法

Also Published As

Publication number Publication date
FI962769L (fi) 1996-07-05
NO962848L (no) 1996-09-06
HU217849B (hu) 2000-04-28
CN1141045A (zh) 1997-01-22
DE69421721T2 (de) 2000-04-27
AU684604B2 (en) 1997-12-18
ATE186732T1 (de) 1999-12-15
WO1995018815A1 (en) 1995-07-13
TW397838B (en) 2000-07-11
DK0738273T3 (da) 2000-04-17
IL112242A0 (en) 1995-03-30
FI962769A0 (fi) 1996-07-05
GR3032614T3 (en) 2000-05-31
AU1553295A (en) 1995-08-01
HU9601848D0 (en) 1996-09-30
CA2179987C (en) 1999-01-19
NZ279030A (en) 1997-05-26
ES2141330T3 (es) 2000-03-16
NO306409B1 (no) 1999-11-01
EP0738273B1 (de) 1999-11-17
DE69421721D1 (de) 1999-12-23
CA2179987A1 (en) 1995-07-13
JPH09511227A (ja) 1997-11-11
EP0738273A1 (de) 1996-10-23
HUT75055A (en) 1997-03-28
NO962848D0 (no) 1996-07-05
KR100330328B1 (ko) 2002-12-05
MX9500363A (es) 1998-04-30
CN1043231C (zh) 1999-05-05
ZA9512B (en) 1995-09-11
FI114396B (fi) 2004-10-15

Similar Documents

Publication Publication Date Title
NO952228L (no) Anvendelse av lamotrigin ved behandling av neurologiske lesjoner relatert til traumatiske skader
CA2002648A1 (en) 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives
GB9407305D0 (en) Pharmaceutical compositions
HUT75055A (en) Monohydrate of (e)-2'-deoxy-2'-(fluoromethylene)cytidine
SE9500566L (sv) L-platta
TR199701212T1 (xx) �drar� tutamama halinin tedavisi i�in alfa IL- agonistlerinin kullan�lmas�.
MX9603091A (es) Intermediarios de cloropirimidina.
EP0334361A3 (de) Durch Acetylen, Cyan oder Allen substituierte Aristeromycin- oder Adenosin-Derivate
ATE201680T1 (de) 2,3,4,5-tetrahydro-1h-3-benzazepin säure- additions-salze
GB2340491A (en) Carbocyclic nucleoside hemisulfate and its use in treating viral infections
EP0347852A3 (de) Neplanocinderivate
BR9811643A (pt) Suplementação quìmica de osso
MY124071A (en) Treatment of viral disease in swine
DE69836087D1 (de) Kortikalknochenimplantat für wirbelfusion nach smith-robinson
ES8704962A1 (es) Un procedimiento para preparar 1b-d-ribofuranosil, 1-2-4-triazol-3-carboxamida.
BR9916043A (pt) Composto, uso do mesmo e de seus saisfarmaceuticamente aceitáveis, e, composiçãofarmacêutica para tratamento de infecções deherpes viral em pacientes
GR3034688T3 (en) Use of 6,7-substituted-2-aminotetralines for preparing pharmaceutical compositions useful for the treatment of septic shock, and antipyretic and antiinflammatory pharmaceutical compositions
EP0459176A3 (en) Oligophosphates with antiviral activity
BR0012380A (pt) 2-amino-benzoxazinonas para o tratamento de vìrus do herpes simples
LTIP1943A (en) Arylating agents, used in the treatment of cancerand disease caused by viral infection
MY101613A (en) Diabrotica larvicidal agents
IT1271291B (it) La melatonina quale riequilibratore fisiologico del rapporto linfocitario th1/th2
EP0210099A3 (en) Use of n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-amino-5-methylsulfamoylbenzamide in the treatment of parkinsons's disease
UA23352A (uk) beta- D- ГЛЮКОЗАМОHІЙHА СІЛЬ alРha-БРОМІЗОВАЛЕРІАHОВОЇ КИСЛОТИ, ЯКА МАЄ ПРОТИВІРУСHУ АКТИВHІСТЬ ВІДHОСHО ВІРУСУ ВЕЗИКУЛЯРHОГО СТОМАТИТУ, ВІРУСУ ПРОСТОГО ГЕРПЕСУ ТА КОРОHАВІРУСУ

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees